RheumaKit Logo

Slide

Making an accurate diagnosis early enough is crucial for arthritis patients, but is a very difficult task for undifferentiated arthritis patients. RheumaKit addresses this complex issue.

Slide

RheumaKit combines gene expression measurements and clinical data.

Slide

Samples are shipped to our facility with an air-transportation validated packaging (UN3373) via express courier.

Slide

Each patient's data are analyzed through an advanced predictive solution to output an early and accurate diagnostic support.

RheumaKit is a set of tools for the management of patients with arthritis, enabling differential diagnosis with RheumaKit-Dx, patient monitoring and clinical studies management with RheumaKit-Timeline, and treatment response prediction / theranosis with RheumaKit-Tx.

RheumaKit-Dx: Differential diagnosis

RheumaKit-Dx is a differential diagnosis tool for patients with undifferentiated arthritis. Its main benefits are to detect earlier patients with rheumatoid arthritis, so as to initiate their treatment as early as possible, and on the other hand, to avoid the initiation of a non-adequate treatment for other patients.
RheumaKit-Dx combines very advanced technologies: a transcriptomic analysis from patient's synovial tissue performed in a central laboratory is combined to clinical information gathered by the clinician, and fed into a predictive model discriminating between Rheumatoid Arthritis, Osteoarthritis and Spondyloarthropathy.

Rheumatoid arthritis

RheumaKit-Dx also delivers a metabolic pathway analysis. This allows the rheumatologist learn more about a single patient metabolic activity, in specific pathways related to existing treatments or disease activity. These precious pieces of information may guide the establishment of a therapeutic strategy by the rheumatologist.

Metabolic pathway analysis

RheumaKit-Timeline Beta: Patient monitoring and clinical studies management

RheumaKit-Timeline allows the recording of a broad range of criteria and scores (diagnosis or disease activity) for each patient separately, nicely arranged in a timeline. Treatments informations are logged as well, for an objective, detailed and effective patient follow-up. Two examples are provided below. The first one shows a patient well under control with a working therapeutic strategy based on Methotrexate and Adalimumab, with decreasing levels of both DAS28-CRP and patient fatigue. A positive ACR/EULAR2010 score is visible early in the timeline.

RheumaKit-Timeline

The second example reports an objective detection of a patient for which the therapy initially based on Methotrexate and Adalimumab needs to be adapted. A second biological DMARD, Infliximab, is chosen, and does not seem to be a good choice either. Yet another month of follow-up should provide sufficient information for the clinician to change the biological DMARD yet another time.

Bad RheumaKit-Timeline

Only a few metrics are reported in these two examples but many more are available. Some are public (i.e. do not require login or registration), as DAS28 (with or without CRP), CDAI, SDAI and HAQ-DI, or ACR/EULAR2010. Many more are accessible only after registration and login, as CRP, ACPA, AAN, HLA-B27, pain, fatigue, radiological involvment, and above all: treatment (initiation, modification, termination).

Another possible application of the tool is its use for the implementation of your own clinical study. The general-purpose « Follow-Up visit clinical record form » is available, from which most possible scores are automatically computed and recorded on the patient timeline!

RheumaKit-Timeline is in « Beta » version, meaning that it is still subject to evolution in the upcoming months. The good news is that RheumaKit Timeline Beta is at this stage accessible to any user, with or without having purchased RheumaKit-Dx kits!

RheumaKit-Tx: Treatment response prediction / theranostic applications

The RheumaKit team is also currently developing tools for explicit treatment response prediction in the field of Rheumatoid Arthritis. At the same time, the tool can also be included in pharmaceutical or biotech companies clinical trials regarding biological DMARDs validation, nicely combined to the data mining expertise of DNAlytics, the developer of RheumaKit.

Quick access

rk-

Calculators

Disease activity

DAS28

DAS28-CRP

CDAI

SDAI

HAQ-DI

RAPID3

Diagnosis

ACR/EULAR 2010